打击传染性腹:治疗和疫苗接种策略的创新
Vivek P Chavda1, Suneetha Vuppu2, Toshika Mishra2
1Department of Pharmaceutics and Pharmaceutical Technology, LM College of Pharmacy, Ahmedabad, Gujarat, India.
Expert review of vaccines
|February 19, 2024
概括
传染性腹是全球主要的健康问题,特别是在发展中国家. 本综述探讨了管理策略,重点关注新型疫苗开发和输送方法,以打击这种严重的儿童疾病.
科学领域:
- 医学微生物学 医学微生物学
- 传染性疾病 传染性疾病
- 疫苗学 疫苗学 疫苗学
背景情况:
- 传染性腹是一个重大的公共卫生挑战,特别是在发展中国家,导致幼儿高死亡率.
- 这种疾病包括急性,侵入性,急性血性和慢性腹,由各种病原体引起,包括细菌,病毒,原生动物和虫.
研究的目的:
- 审查当前传染性腹的现状,包括其类型和管理方法.
- 广泛讨论感染性腹的预防,治疗和疫苗接种策略.
- 探索疫苗开发,输送方法和未来研究方向的进展.
主要方法:
- 关于传染性腹,其分类和致病剂的文献综述.
- 分析当前和新兴的疫苗接种策略,包括优势和局限性.
- 探索新的疫苗开发方法和免疫路线.
主要成果:
- 传染性腹仍然是一个关键的健康问题,各种病原性原因.
- 疫苗接种策略是管理的关键组成部分,正在进行改进疫苗的研究.
- 像鼻喷雾剂和植物性疫苗这样的创新输送方法显示出具有成本效益和更广泛的可访问性.
结论:
- 传染性腹的有效管理需要一个多方面的方法,整合预防,治疗和疫苗接种.
- 对新型疫苗技术和替代性输送系统的持续研究对全球健康至关重要.
- 未来的研究应该集中于识别持久性病原体和优化治疗结果.
相关概念视频
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
119
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
119
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Drugs for Treatment of Diarrhea-Predominant IBS
170
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
170
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
334
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
334
Vaccinations
44.5K
Overview
44.5K
Inflammatory Bowel Disease V: Surgical Management
145
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
145


